Design and endpoints of clinical trials in hepatocellular carcinoma
The design of clinical trials in hepatocellular carcinoma (HCC) is complex because many
patients have concurrent liver disease, which can confound the assessment of clinical …
patients have concurrent liver disease, which can confound the assessment of clinical …
The treatment of chronic viral hepatitis
JH Hoofnagle, AM Di Bisceglie - New England Journal of …, 1997 - Mass Medical Soc
Chronic viral hepatitis is the principal cause of chronic liver disease, cirrhosis, and
hepatocellular carcinoma in the world and now ranks as the chief reason for liver …
hepatocellular carcinoma in the world and now ranks as the chief reason for liver …
[PDF][PDF] Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease
This document presents the official position of the American Association for the Study of
Liver Diseases (AASLD) on the application of serum alanine aminotransferase (ALT) activity …
Liver Diseases (AASLD) on the application of serum alanine aminotransferase (ALT) activity …
Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions
EM Brunt, CG Janney, AM Di Bisceglie… - Official journal of the …, 1999 - journals.lww.com
OJECTIVE: Steatohepatitis is a morphological pattern of liver injury that may be seen in
alcoholic or nonalcoholic liver disease. This pattern may occur with obesity, diabetes, the …
alcoholic or nonalcoholic liver disease. This pattern may occur with obesity, diabetes, the …
[HTML][HTML] Telaprevir for previously untreated chronic hepatitis C virus infection
IM Jacobson, JG McHutchison… - … England Journal of …, 2011 - Mass Medical Soc
Background In phase 2 trials, telaprevir, a hepatitis C virus (HCV) genotype 1 protease
inhibitor, in combination with peginterferon–ribavirin, as compared with peginterferon …
inhibitor, in combination with peginterferon–ribavirin, as compared with peginterferon …
[HTML][HTML] Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection
Background Effective treatment for hepatitis C virus (HCV) genotype 1 infection in patients
who have not had a sustained virologic response to prior interferon-based therapy …
who have not had a sustained virologic response to prior interferon-based therapy …
[HTML][HTML] Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis
Background High rates of sustained virologic response were observed among patients with
hepatitis C virus (HCV) infection who received 12 weeks of treatment with the nucleotide …
hepatitis C virus (HCV) infection who received 12 weeks of treatment with the nucleotide …
[HTML][HTML] Replacement therapy for inherited enzyme deficiency—macrophage-targeted glucocerebrosidase for Gaucher's disease
NW Barton, RO Brady, JM Dambrosia… - … England Journal of …, 1991 - Mass Medical Soc
Abstract Background and Methods. Gaucher's disease, the most prevalent of the
sphingolipid storage disorders, is caused by a deficiency of the enzyme glucocerebrosidase …
sphingolipid storage disorders, is caused by a deficiency of the enzyme glucocerebrosidase …
Recombinant interferon alfa therapy for chronic hepatitis C
AM Di Bisceglie, P Martin, C Kassianides… - … England Journal of …, 1989 - Mass Medical Soc
Infection with the hepatitis C virus may result in chronic liver disease for which no effective
therapy is now available. We studied the effects of recombinant human interferon alfa in a …
therapy is now available. We studied the effects of recombinant human interferon alfa in a …
Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon
JH Hoofnagle, KD Mullen, DB Jones… - … England Journal of …, 1986 - Mass Medical Soc
We treated 10 patients who had chronic non-A, non-B hepatitis with recombinant human
alpha interferon in varying doses (0.5 to 5 million units) daily, every other day, or three times …
alpha interferon in varying doses (0.5 to 5 million units) daily, every other day, or three times …